Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.
暂无分享,去创建一个
E. P. Dellinger | J. Bartlett | E. Baron | A. Nathens | J. Solomkin | T. Buchman | J. Mazuski | R. Sawyer | J. Dipiro | A. Chow | S. Gorbach | J. Jernigan | E. Dellinger | John Jernigan
[1] J. Griffith,et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections , 1996, European Journal of Clinical Microbiology and Infectious Diseases.
[2] N. Christou,et al. Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections: Results of a Double-Blind, Randomized Comparative Phase III Trial , 2003, Annals of surgery.
[3] S. Jenkins,et al. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria ; Approved Standard — Seventh Edition , 2003 .
[4] K. Aldridge,et al. In Vitro Susceptibilities of the Bacteroides fragilis Group Species: Change in Isolation Rates Significantly Affects Overall Susceptibility Data , 2002, Journal of Clinical Microbiology.
[5] A. Nathens,et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. , 2002, Surgical infections.
[6] A. Bisno,et al. Diagnosis of strep throat in adults: are clinical criteria really good enough? , 2002, Clinical Infectious Diseases.
[7] D. Snydman,et al. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] J. Coast,et al. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness , 2002, Journal of health services research & policy.
[9] A. Nathens,et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. , 2002, Surgical infections.
[10] M A Kish,et al. Guide to development of practice guidelines. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] S. Wilson,et al. Results of a Clinical Trial of Clinafloxacin Versus Imipenem/Cilastatin for Intraabdominal Infections , 2001, Annals of surgery.
[12] V. Dev,et al. Complicated Appendicitis: Is There a Minimum Intravenous Antibiotic Requirement? A Prospective Randomized Trial , 2000, The American surgeon.
[13] P. Lipsett,et al. Comparison of Intravenous/Oral Ciprofloxacin Plus Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections , 2000, Annals of surgery.
[14] D. Snydman,et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] D. Snydman,et al. Multicenter Study of In Vitro Susceptibility of theBacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996 , 1999, Antimicrobial Agents and Chemotherapy.
[16] H. Forssell,et al. Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections. , 1999, The European journal of surgery = Acta chirurgica.
[17] H. Levy,et al. Prophylactic Antibiotics for Severe Acute Pancreatitis: The Beginning of an Era , 1999, Pharmacotherapy.
[18] M. Silen,et al. The impact of intraoperative culture on treatment and outcome in children with perforated appendicitis. , 1999, Journal of pediatric surgery.
[19] R. Bennion,et al. Ticarcillin/Clavulanate versus Imipenem/Cilistatin for the Treatment of Infections Associated with Gangrenous and Perforated Appendicitis , 1999, The American surgeon.
[20] C. Ohmann,et al. Risk factors associated with intraabdominal infections: a prospective multicenter study , 1999, Langenbeck's Archives of Surgery.
[21] J. Brogard,et al. Biliary tract infections: a guide to drug treatment. , 1999, Drugs.
[22] C. Ohmann,et al. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. , 1999, Langenbeck's archives of surgery.
[23] D. Luke,et al. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. , 1998, American journal of surgery.
[24] R. Chioléro,et al. Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis , 1998, Antimicrobial Agents and Chemotherapy.
[25] C. Burnweit,et al. Is abdominal cavity culture of any value in appendicitis? , 1998, American journal of surgery.
[26] B. Rau,et al. Role of ultrasonographically guided fine‐needle aspiration cytology in the diagnosis of infected pancreatic necrosis , 1998, The British journal of surgery.
[27] P. Barie,et al. A Randomized, Double-blind Clinical Trial Comparing Cefepime Plus Metronidazole With Imipenem-Cilastatin in the Treatment of Complicated Intra-abdominal Infections , 1997 .
[28] D. Gerding,et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. , 1997, Infection control and hospital epidemiology.
[29] E. Taylor,et al. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. , 1997, The Journal of antimicrobial chemotherapy.
[30] A. Basoli,et al. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. , 1997, Scandinavian journal of infectious diseases.
[31] P. Barie,et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. , 1997, Archives of surgery.
[32] D. Snydman,et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] J. Bohnen,et al. Management of Intra-abdominal Infections: The Case for Intraoperative Cultures and Comprehensive Broad-spectrum Antibiotic Coverage , 1996 .
[34] P. Montravers,et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] K. Faulkner,et al. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. , 1996, The Journal of antimicrobial chemotherapy.
[36] T. Berne,et al. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. , 1996, Journal of the American College of Surgeons.
[37] J. Bohnen,et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. , 1996, Annals of surgery.
[38] D. Gerding,et al. Does antibiotic restriction prevent resistance? , 1996, New horizons.
[39] A. Viste,et al. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. , 1996, Scandinavian journal of infectious diseases.
[40] S. Wilson,et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] S. Geroulanos. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. , 1995, The Journal of antimicrobial chemotherapy.
[42] D. Pezet,et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. , 1995, The Journal of antimicrobial chemotherapy.
[43] P. Schauer,et al. Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. , 1995, The American surgeon.
[44] B. Bäckstrand,et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. , 1995, The Journal of antimicrobial chemotherapy.
[45] P. Barie,et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. , 1993, The American surgeon.
[46] C. Ohmann,et al. Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. , 1993, The European journal of surgery = Acta chirurgica.
[47] Jeffrey W. Smith,et al. Efficacy of a β-Lactamase Inhibitor Combination for Serious Intra-abdominal Infections , 1993 .
[48] P. Barie,et al. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. , 1993, Archives of surgery.
[49] Nord Ce,et al. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. , 1993 .
[50] R. Wilson,et al. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. , 1993, Annals of surgery.
[51] C. Nord,et al. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. , 1993, The Journal of antimicrobial chemotherapy.
[52] B. Bäckstrand,et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections , 1992, Antimicrobial Agents and Chemotherapy.
[53] J. Bartlett,et al. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[54] A. Awada,et al. Streptococcal and enterococcal bacteremia in patients with cancer. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[55] D. Snydman,et al. Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis , 1992, Antimicrobial Agents and Chemotherapy.
[56] J. Bohnen,et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. , 1992, Archives of surgery.
[57] D. Dunn,et al. Antibiotic treatment for surgical peritonitis. , 1991, Annals of surgery.
[58] L. Navér,et al. Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. , 1991, The European journal of surgery = Acta chirurgica.
[59] K. Sirinek,et al. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. , 1991, Surgery, gynecology & obstetrics.
[60] J. Solomkin,et al. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. , 1990, Annals of surgery.
[61] N. Christou,et al. Imipenem versus tobramycin--antianaerobe antibiotic therapy in intra-abdominal infections. , 1990, Canadian journal of surgery. Journal canadien de chirurgie.
[62] M. Bergeron,et al. Pathogenic factors in aminoglycoside-induced nephrotoxicity. , 1990, Toxicology letters.
[63] P. Francioli,et al. CLINICAL SIGNIFICANCE OF CANDIDA ISOLATED FROM PERITONEUM IN SURGICAL PATIENTS , 1989, The Lancet.
[64] S. Wilson,et al. Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin. , 1988, American journal of surgery.
[65] N. Jacobus,et al. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation , 1988, Antimicrobial Agents and Chemotherapy.
[66] D. Snydman,et al. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates. , 1987, Diagnostic microbiology and infectious disease.
[67] Peoples Jb. Candida and perforated peptic ulcers. , 1986 .
[68] J. Peoples. Candida and perforated peptic ulcers. , 1986, Surgery.
[69] T. Berne,et al. The role of Pseudomonas species in patients treated with ampicillin and Sulbactam for gangrenous and perforated appendicitis. , 1985, Surgery, gynecology & obstetrics.
[70] J. Meakins,et al. Surgical infection stratification system for intra-abdominal infection. Multicenter trial. , 1985, Archives of surgery.
[71] Fong Iw. Septic complications of perforated peptic ulcer. , 1983 .
[72] I. Fong. Septic complications of perforated peptic ulcer. , 1983, Canadian journal of surgery. Journal canadien de chirurgie.
[73] T. Berne,et al. Antibiotic management of surgically treated gangrenous or perforated appendicitis. Comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone. , 1982, American journal of surgery.
[74] J. Boey,et al. Bacteria and septic complications in patients with perforated duodenal ulcers. , 1982, American journal of surgery.
[75] D. Kasper,et al. Cellular immunity to Bacteroides fragilis capsular polysaccharide , 1982, The Journal of experimental medicine.
[76] E. Dellinger,et al. Implications of Leukocytosis and Fever at Conclusion of Antibiotic Therapy for Intra‐abdominal Sepsis , 1982, Annals of surgery.
[77] R. L. Simmons,et al. The role of Candida in intraperitoneal infections. , 1980, Surgery.
[78] E. Dellinger,et al. Leukocytosis at termination of antibiotic therapy: its importance for intra-abdominal sepsis. , 1980, Archives of surgery.